UTSI [UTSTARCOM] UPLOAD: (Original Filing)
[]
[EX-99.77B ACCT LTTR 2 jpmorganchinaregionfundannua.htm EX-99.77B ACCT LTTR]
[Xinyuan Real Estate Co., Ltd. Announces Fourth quarter 2014 FINANCIAL RESULTS BEIJING, China, February 27, 2015 Highlights for the Fourth Quarter 2014 · Total fourth quarter revenues were US$362.9 million, a 121.8% increase from US$163.6 million recorded in the third quarter of 2014 and a 25.5% increase from US$289.2 million recorded in the fourth quarter of 2013. Contract sales totaled] []
[HANWHA Q CELLS ANNOUNCES EGM Company Hanwha Q CELLS EGM SEOUL, SOUTH KOREA February 27, 2015 Hanwha Q CELLS Co., Ltd. (the AOA Proposal The Company will transact no other business at the EGM, except for business properly brought before the EGM or any adjournment or postponement thereof. ADSs Depositary Only holders of ordinary shares as] [Hanwha Q CELLS Co., Ltd. Seong Woo Nam Chairman and CEO 6-K 1 d880290d6k.htm FORM 6-K]
[HANWHA Q CELLS ANNOUNCES EGM Company Hanwha Q CELLS EGM SEOUL, SOUTH KOREA February 27, 2015 Hanwha Q CELLS Co., Ltd. (the AOA Proposal The Company will transact no other business at the EGM, except for business properly brought before the EGM or any adjournment or postponement thereof. ADSs Depositary Only holders of ordinary shares as] [Hanwha Q CELLS Co., Ltd. Seong Woo Nam Chairman and CEO 6-K 1 d880290d6k.htm FORM 6-K]
[CHENGDU, China, Feb. 26, 2015 /PRNewswire/ - Tianyin Pharmaceutical Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), received notice on February 24, 2015 from the NYSE MKT LLC (the "Exchange") indicating that the Company is below certain of the Exchange's continued listing standards,] []
[CHENGDU, China, Feb. 26, 2015 /PRNewswire/ - Tianyin Pharmaceutical Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), received notice on February 24, 2015 from the NYSE MKT LLC (the "Exchange") indicating that the Company is below certain of the Exchange's continued listing standards,] []